Natural product-based anti-emetic ingredient discovery using quantum electrochemistry
Qnity Bio offers a novel screening platform using quantum electrochemistry to discover anti-emetic ingredients from natural products. This method reduces costs and enhances accuracy by using attomolar concentrations and preventing non-specific binding.
Overview
Qnity Bio presents an innovative solution for discovering anti-emetic ingredients using natural products. By employing a cutting-edge screening device based on quantum electrochemistry, this platform targets nausea-related compounds efficiently and cost-effectively. The solution minimizes the need for large volumes of test compounds and circumvents nonspecific binding, making it ideal for developing a robust pipeline of natural anti-emetic agents and their synthetic analogs. The platform's versatility also allows for the exploration of additional therapeutic activities.
Technical specifications
Qnity Bio's technology utilizes sensors that measure binding affinity through quantum electrochemistry. Key features include:
- Low concentration usage: Tests are conducted with attomolar concentrations, significantly reducing assay costs.
- Directional immobilization: Sensors feature highly directional immobilization, minimizing non-specific binding and enhancing assay accuracy.
- Comprehensive data collection: Provides biophysical and biochemical metrics such as IC50, EC50, ADMET, and PKPD.
- Flexible library usage: Compatible with existing natural product libraries or new library development.
Technology readiness level
The technology is currently at TRL 4, having been validated in laboratory settings. The ongoing development includes stages like target panel selection, library development, assay creation, and comprehensive screening processes, positioning it for further commercialization and real-world application.
About Qnity Bio
Qnity Bio is a deep-tech company that has developed a quantum-electrochemical platform designed to transform molecular screening and drug discovery. Their technology utilizes custom-built chips equipped with nanogold-silicon electrodes and quantum sensing capabilities to detect molecular binding events and chemical reactions at attomolar concentrations. By providing label-free, real-time analysis, the system offers significantly higher sensitivity compared to traditional methods such as SPR and ELISA, enabling researchers to screen molecule sizes ranging from small organics to complex biologics with greater precision and scalability.
This technology addresses critical bottlenecks in pharmaceutical research, where traditional screening is often slow, expensive, and limited by low resolution. By delivering accessible, high-throughput molecular data, Qnity aims to accelerate preclinical validation and de-risk drug development decisions for innovators in the pharmaceutical and biotechnology industries. The company has engaged in strategic pilots with industry partners and is supported by specialized scientific expertise and global research initiatives, positioning its platform to expand into broader applications across proteomics, genomics, and metabolomics.
delivered to your inbox.